6 recruiting, 6 unknown, 5 completed, 2 active not recruiting. 23 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 23 | Recruiting 6, Unknown 6, Completed 5, Active not recruiting 2, Not yet recruiting 2, Terminated 2 |
Follow Acute Myeloid Leukemia: new trials by email Literature Review of Acute Myeloid Leukemia trials Research Report on Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C) - Acute Myeloid Leukemia, Pediatric AML | Early Phase 1 | Recruiting | Baylor College of Medicine | 36 | 2025-10-22 | 2026-08-24 |
| Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia CD117 CAR T-cells - Acute Myeloid Leukemia | Early Phase 1 | Recruiting | Zhejiang University | 50 | 2025-09-05 | 2025-08-27 |
| XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia Personalized neoantigen tumor vaccine, PD-1 inhibitor - Acute Myeloid Leukemia | Early Phase 1 | Recruiting | Shanghai Jiao Tong University School of Medicine | 60 | 2025-05-30 | 2025-05-20 |
| A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia CD33 CAR T-cells - Acute Myeloid Leukemia | Early Phase 1 | Recruiting | Zhejiang University | 27 | 2025-01-10 | 2025-01-07 |
| Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML CLL1 and CD38 dual-target CAR-T injection - Acute Myeloid Leukemia | Early Phase 1 | Terminated | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 3 | 2023-10-10 | 2025-02-26 |
| Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT allogenic NK cells - Acute Myeloid Leukemia | Early Phase 1 | Unknown | Xuzhou Medical University | 12 | 2023-03-01 | 2023-02-27 |
| CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases CD70 CAR T-cells - Acute Myeloid Leukemia, Non-hodgkin's Lymphoma | Early Phase 1 | Recruiting | Zhejiang University | 108 | 2021-11-18 | 2021-11-04 |
| Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia Anti-CLL1 CART cells - Acute Myeloid Leukemia | Early Phase 1 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 100 | 2021-09-14 | 2023-07-13 |
| Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors Biopsy, Biospecimen Collection, Electronic Health Record Review - Acute Myeloid Leukemia, Myeloid Leukemia | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2021-06-30 | 2026-09-22 |
| NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia NKG2D CAR T-cells - Acute Myeloid Leukemia | Early Phase 1 | Not yet recruiting | Zhejiang University | 36 | 2021-01-15 | 2020-12-08 |
| Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia Anti-CD33/CLL1 CAR-NK Cells - Acute Myeloid Leukemia | Early Phase 1 | Unknown | Wuxi People's Hospital | 18 | 2020-11-30 | 2022-01-31 |
| IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia IL3 CAR T-cells - Acute Myeloid Leukemia | Early Phase 1 | Not yet recruiting | Zhejiang University | 36 | 2020-11-15 | 2020-10-27 |
| TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia Azacitidine, Dubermatinib - Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Early Phase 1 | Completed | Uma Borate | 3 | 2020-11-05 | 2023-02-06 |
| Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant Hyperbaric oxygen - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Early Phase 1 | Recruiting | Omar Aljitawi | 24 | 2020-07-01 | 2026-06-03 |
| Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease haploid allogeneic NK cell therapy - Acute Myeloid Leukemia | Early Phase 1 | Unknown | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China | 6 | 2020-01-01 | 2020-07-29 |
| Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) Atovaquone, Cytarabine, Daunorubicin - Acute Myeloid Leukemia | Early Phase 1 | Completed | Baylor College of Medicine | 26 | 2018-07-10 | 2026-06-23 |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CD123-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2019-11-12 |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CLL1-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2021-05-19 |
| Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18 - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Early Phase 1 | Active not recruiting | City of Hope Medical Center | 82 | 2018-02-15 | 2026-06-08 |
| Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers Trivalent Influenza Vaccine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Early Phase 1 | Completed | Roswell Park Cancer Institute | 130 | 2017-10-17 | 2023-06-06 |
Showing 20 of 23. Sign in to see all of them.
Leukemia, Myeloid, Acute (23) · Myelodysplastic Syndromes (5) · Hematologic Neoplasms (2) · Leukemia (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid (2) · Myeloproliferative Disorders (2) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Neoplasm, Residual (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (23) · Hemic and Lymphatic Diseases (23) · Neoplasms (23) · Neoplasms by Histologic Type (23) · Leukemia (21) · Leukemia, Myeloid (21) · Bone Marrow Diseases (5) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3) · Disease Attributes (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3)
Cytarabine (2) · Etoposide (2) · Atovaquone (1) · Azacitidine (1) · Biopsy (1) · Daunorubicin (1) · FluBlok (1) · FluLaval (1) · Fluzone High-Dose (1) · Gemtuzumab (1) · Hyperbaric Oxygenation (1) · Idarubicin (1) · Immune Checkpoint Inhibitors (1) · Influenza Vaccines (1) · Magnetic Resonance Spectroscopy (1)
Zhejiang University (5) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (2) · Baylor College of Medicine (2) · iCell Gene Therapeutics (2) · Amgen (1) · City of Hope Medical Center (1) · Jazz Pharmaceuticals (1) · M.D. Anderson Cancer Center (1) · Omar Aljitawi (1) · Roswell Park Cancer Institute (1) · Shanghai Jiao Tong University School of Medicine (1) · Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China (1) · Uma Borate (1) · University of Chicago (1) · Wuxi People's Hospital (1)
China (13) · United States (10) · Australia (1) · Germany (1)
Fang Liu, MD, PhD (2) · He Huang, MD (2) · Hongyu Zhang, MD, PhD (2) · Alexandra Stevens, MD (1) · Bouthaina S Dabaja (1) · Elizabeth A Griffiths (1) · Jeffrey Y Wong (1) · Justin Kline, MD (1) · Kailin Xu, M.D., Ph.D. (1) · Omar S Aljitawi, MBBS (1) · Paul J Shami, M.D. (1) · Sanbin Wang (1) · Uma Borate, MD (1) · Xian Zhang (1)
PMID 33439382, PMID 35468680, PMID 35973200, PMID 37093350, PMID 42040934
2017 (1), P30CA033572 (1)